This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

SAVINGS DEADLINE EXPIRES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Alain Noncovich, Ph.D.
Associate Director of Chemistry at RayzeBio
Speaker

Profile

Dr. Noncovich is the Associate Director of Chemistry at RayzeBio and has over 15 years of industrial drug discovery experience specializing in the medicinal chemistry of small molecules, bioconjugates and peptides in multiple therapeutic areas. At RayzeBio, Alain has led the chemistry efforts on multiple programs from hit identification to lead optimization and Development candidate selection and has helped advance the principles for vector, linker and chelator optimization for RPT candidates. Prior to his current role, Alain made significant contributions at Cidara Therapeutics leading to the development of the anti-flu clinical candidate CD388, being studied in Phase II trials in partnership with J&J. Preceding this, his tenure at Senomyx Inc. saw him as the leading chemist responsible for the discovery and development of the GRAS approved coolant flavor FEMA4809. Alain earned his Ph.D. in Medicinal Chemistry from Università degli Studi del Piemonte Orientale under the guidance of Professor G. B. Appendino, where he worked on the synthesis and evaluation of C-seco-taxanes. He subsequently conducted postdoctoral studies in natural product synthesis at TSRI under Professor K. C. Nicolaou.

Agenda Sessions

  • Development of Radiopharmaceutical Therapy agents for treatment of GPC3-Expressing tumors

    10:45am